Printer Friendly

MediciNova awarded Notice of Allowance for MN-001 and MN-002 for NASH from US Patent and Trademark Office.

M2 PHARMA-February 4, 2015-MediciNova awarded Notice of Allowance for MN-001 and MN-002 for NASH from US Patent and Trademark Office

(C)2015 M2 COMMUNICATIONS

Biopharmaceutical company MediciNova (Nasdaq GM:MNOV) disclosed on Tuesday the receipt of a Notice of Allowance from the US Patent and Trademark Office for a pending patent application which covers MN-001 and MN-002 for the treatment of NASH (nonalcoholic steatohepatitis).

Upon issue, the patent maturing from this allowed patent application is expected to expire no earlier than December 2032, added the company.

The company said the allowed claims cover a method of treating NASH, a method of reducing liver inflammation in NASH, a method of reducing hepatic fibrosis in NASH and a method of reducing damage to liver cells in NASH using MN-001 (tipelukast) or MN-002 (a major metabolite of MN-001). The allowed claims cover oral administration, tablets and capsules, as well as liquid dosage forms.

According to the company, MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) and inhibition of 5-lipoxygenase.

Nonalcoholic steatohepatitis (NASH) is a condition in which there is fat in the liver along with inflammation and damage to liver cells. NASH is a common liver disease that resembles alcoholic liver disease but occurs in people who drink little or no alcohol.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Feb 4, 2015
Words:248
Previous Article:Theravance Biopharma collaborates with Mylan to develop and commercialise TD-4208.
Next Article:Mallinckrodt posts better non-GAAP adjusted net income of USD213.8m in Q1 Fiscal 2015.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters